Analysed ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) News Sources
Alpha Tau Medical Shares Early REGAIN Data: 2 Complete Responses in Glioblastoma Study
11-05-2026
marketbeat.com
Alpha Tau Medical Sets Up Catalyst-Rich 2026 as Key Cancer Trial Data Nears
29-05-2026
marketbeat.com
Alpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients
03-06-2026
yahoo.com
DRTS Stock Shot Up A Whopping 22% Today – Why A $196.5M Prostate Cancer Deal Got Investors Buzzing
03-06-2026
stocktwits.com
Alpha Tau Successfully Treats First Recurrent Glioblastoma Patient Outside of the United States with Alpha DaRT® at Hadassah University Medical Center in Israel
23-06-2026
yahoo.com
Oramed Releases Letter to Shareholders, Highlighting Russell 2000/3000 Index Inclusion, Scilex Loan Repayment, Strategic Portfolio Appreciation, and a Strengthened Balance Sheet
25-06-2026
yahoo.com
Alpha Tau Medical’s (DRTS) First International Brain Cancer Use Tests The Breadth Of Its Alpha DaRT Platform
27-06-2026
yahoo.com
What is the current price of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)?
The current price of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) is $3.66.
ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) absolute price change since previous trading day?
The absolute price change of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) since the previous trading day is $-0.2.
ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) percentage price change since previous trading day?
The percentage price change of ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) since the previous trading day is -5.1813%.
What is the most recent average sentiment score for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)?
The most recent average sentiment score for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) is 82 out of 100.
What is the most recent average sentiment for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)?
The most recent sentiment for ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ) is .
SEC-8K** Filing Available For ALPHA TAU MEDICAL LTD -27 (DRTSW:NASDAQ)
** material developments that could impact a company's financial condition or stock price.
Author: MattELab
MattELab is the founder and lead developer of SentientMerchant. With a Computer Science and Quantitative Finance background from a T10 university, he brings over 6 years of expertise in NLP, programmatic SEO, and full-stack development to build highly scalable AI and FinTech solutions.